Company intelligence / Profile preview

Pneumagen

St Andrews, Fife, United Kingdompneumagen.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Neumifil demonstrated a clinically significant reduction in the incidence and severity of symptomatic influenza infection in a Phase 2 human challenge study. The drug was well tolerated with no new safety signals compared to placebo. Further studies are planned to evaluate efficacy in patients with chronic lung disease at risk of viral-induced exacerbations.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Engineered multivalent Carbohydrate Binding Modules (mCBMs)Intranasal antivirals
Industry: Biotech

Drug pipeline

2 assets

HEX17

1 more asset in the full pipeline.

Request access →

Partnerships

hVIVO/Open Orphan plc – conducting human challenge studies for clinical trialsFUJIFILM Diosynth Biotechnologies – supporting process development and scale-up manufacturing for clinical trials

Beyond the preview

Go deeper on Pneumagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pneumagen.

Explore the full profile